March 7, 2024

Profound Research: Spotlight on Faisal Musa, M.D., Medical Oncologist

At Profound Research, we strive to highlight the remarkable individuals who contribute to the advancement of medical science and patient care through clinical research. Today, we have the privilege of sharing insights from Faisal Musa, M.D., a Medical Oncologist and Profound Research Principal Investigator at Michigan Healthcare Professionals (MHP) located in Dearborn. Let's delve into Dr. Musa's journey in clinical research, his insights, and his contributions to the field.

What led you to clinical research?

Oncology is a dynamic and ever-evolving field that presents continuous challenges. My passion for making a meaningful difference in patients' lives, coupled with the opportunity to explore novel treatments and therapies, drew me towards clinical research. Being at the forefront of discovering new ways to combat cancer and improve outcomes for patients is immensely fulfilling.

What is your favorite part about working in clinical research?

One of the most exhilarating aspects of clinical research is the opportunity to venture into the unknown. Exploring the efficacy and potential side effects of new medications and treatments not only expands our understanding but also holds the promise of revolutionizing patient care. Additionally, being involved in pioneering therapies that could shape the future of medicine is truly rewarding.

Do you have a particular success story that stuck with you?

Indeed, I have a memorable success story involving a Multiple Myeloma patient who has been on Revlimid successfully for over 10 years, with stable disease. Witnessing the tangible impact of innovative treatments on patients' lives reaffirms the importance of clinical research and motivates me to continue pushing boundaries in oncology.

What would you want people to know about clinical research?

It's crucial for individuals to understand that while clinical trials may not offer immediate solutions for every condition, they play an indispensable role in advancing medical knowledge and developing new therapies. By participating in clinical trials, patients not only contribute to the collective effort in finding better treatments but also gain access to potentially groundbreaking interventions.

What are some hobbies/interests of yours outside of clinical research?

Outside of my professional endeavors, I am an avid soccer enthusiast. Engaging in sports not only provides a welcome respite from the demands of clinical research but also promotes physical well-being and a balanced lifestyle.

Is there any other information you’d like sponsors or patients to know about you?

As a community hematologist and oncologist, I am committed to providing comprehensive care across a wide spectrum of hematological disorders and solid tumors. Additionally, serving as a System Professor at Wayne State University and holding the position of Section Chief of Medical Oncology at Corewell Health System in Dearborn underscores my dedication to academic excellence and clinical leadership.

In Closing

The expertise, dedication, and groundbreaking research of Dr. Musa have not only elevated the field of medical oncology but have also touched the lives of countless patients. His insights shed light on the transformative potential of clinical trials and the profound impact they can have on individuals battling cancer.

As we conclude this spotlight, we are reminded of the profound impact that passionate individuals can have on our collective well-being. We encourage you to stay engaged with Profound Research as we continue to spotlight those who shape the future of science and healthcare. We eagerly anticipate sharing more visionary leaders in our upcoming editions of the Profound Research Spotlight Series.

February 8, 2024

Profound Research Charts Exciting Growth Path with Hire of CEO and Strategic Promotions of Key Leadership Roles

Nashville, TN - [February 8, 2024] - Profound Research, a leading clinical trial site network, today announced key leadership appointments aimed at driving innovation and continuing growth. These appointments include Lora Parahovnik, Ph.D., MBA, as Chief Executive Officer, along with the internal promotions of Marty Anderson to Chief Operations Officer and Christopher Church to Chief Commercial Officer.

Dr. Parahovnik brings extensive experience to her new role. She most recently served as CEO at Accel Research Sites Network where her teams set industry benchmarks for patient-centric clinical research within modern healthcare ecosystems. 

“I am honored to join an organization with a vision deeply rooted in improving patient lives, ensuring access to innovative treatments, and propelling scientific and medical progress,” said Parahovnik.  “It is a privilege to lead a team whose mission aligns seamlessly with my own values and aspirations.” 

Marty Anderson, promoted to Chief Operations Officer, has been a pivotal figure in Profound's journey, spearheading operations since the company's inception. Her 30-year experience in the clinical trial industry and dedication to operational excellence position Profound for continued growth in both quality and market presence. 

Christopher Church, promoted to Chief Commercial Officer, brings a wealth of experience in building successful commercial teams and driving business development initiatives within the clinical trial industry. His strategic leadership has been focal in expanding Profound's therapeutic area expansion and driving revenue growth. 

Dr. Jonathan Feldstein, President and co-founder of Profound Research, expressed his enthusiasm for these appointments, saying, "We are thrilled to welcome Lora Parahovnik as our CEO and to announce the well-deserved promotions of Marty Anderson and Christopher Church. Their combined ability and leadership will be instrumental in driving Profound Research forward as an industry leader dedicated to medical innovation and patient access to those treatments.”  

About Profound Research

Profound Research is an integrated clinical research network comprising trial sites embedded into independent physician practices. With a mission to expand access to clinical research for community patients and offer more therapeutic options to community physicians, Profound Research operates across Southern California, the Detroit metropolitan area, and is expanding nationwide. The company boasts a team of experienced research professionals dedicated to providing high-quality clinical research support to physicians and their patients. 

For inquiries, please contact:

info@profoundresearch.io 

Profound Research LLC 

January 31, 2024

Enhancing Cardiovascular Research: Profound’s Collaborative Approach with MHP CAVA

Clinical research plays a crucial role in advancing medical knowledge, with sponsors and contract research organizations frequently facing the challenges posed by the intricacies of cardiovascular studies. One prevalent challenge is the limited availability of US-based sites, prompting sponsors to seek new, community-based alternatives. Profound Research empathizes with these challenges and has developed a thoughtful approach to simplify a comprehensive range of clinical studies, including cardiovascular.

Understanding Sponsor Challenges:

Sponsors navigating the intricate landscape of cardiovascular research often encounter hurdles due to a restricted US-based site footprint. This saturation poses challenges in conducting studies efficiently and reaching diverse patient populations. Profound Research acknowledges this dilemma and has tailored its model to provide sponsors with a solution that overcomes typical challenges and aligns with their goals.

The Key Solutions: Community-based Partnerships and Central Support

To solve these challenges in the cardiovascular space, Profound Research, whose network also includes MHP TriaAtria and Southern California Heart Specialists, has formed a partnership with Michigan Healthcare Professionals Cardiology and Vascular Associates (MHP CAVA). Situated at 42557 Woodward Avenue, Suite 200, Bloomfield Hills, MI 48304, MHP CAVA serves a diverse range of populations just 30 minutes outside of Detroit.

One: Leadership at MHP CAVA

At the forefront of this collaborative effort are two highly experienced interventional cardiologists: Abdul R. Halabi, M.D., FACC and Kirit Patel, M.D., FACC. With a collective experience exceeding fifty years, these providers have dedicated themselves to advancing cardiovascular medicine and have played pivotal roles as principal or sub-investigators in over seventy research studies. Their commitment to patient well-being and innovation aligns seamlessly with Profound's mission of actively connecting patients to advanced therapeutic options in their own communities.

Two: Profound's Comprehensive, Centralized Support

Beyond establishing strategic relationships and connecting sponsors with community-based providers, Profound Research offers central support to sponsors, covering crucial aspects such as technology, feasibility, budget and contract, regulatory and startup processes, as well as quality control. This centralized support ensures that sponsors can concentrate on the scientific aspects of their studies while Profound handles the logistical and administrative challenges, resulting in expedited progress and truncated timelines from start-up on through the fruition of clinical advancements. To learn more about Profound's approach to centralized support, click here.

Taking Action: How Sponsors Can Benefit

To get started, Profound Research invites sponsors to include any one of our four cardiovascular research sites in ongoing and planned feasibility processes for cardiovascular studies. By doing so, sponsors will access a largely untapped patient population along with the expertise of our highly skilled team at MHP CAVA. We look forward to discussing with innovators in the cardiovascular space how Profound’s cardiovascular sites can tailor support to specific research needs.

Conclusion

In cardiovascular research, Profound Research emerges as a preferred collaborative partner, offering thoughtful solutions to sponsors seeking efficient and impactful studies. The partnership with MHP CAVA, coupled with Profound's comprehensive support, creates an inviting opportunity for sponsors to advance their research goals seamlessly. By engaging with Profound's feasibility team at feasibility@profoundresearch.io, sponsors can take the first step toward transforming their cardiovascular research initiatives.

January 4, 2024

Bridging the Gap: How Profound is Harnessing the Power of Diversity for Robust Clinical Trial Outcomes

Byline: Erem Latif

Over the past 12 years, there has been a growing emphasis on exploring the social determinants of health. Our comprehension of how economic stability, community dynamics, access to resources, and the quality of education, among various other nuanced elements, significantly influence an individual's health, quality of life, and overall outcomes has substantially expanded. The U.S. Office of Disease Prevention and Health Promotion has even launched the Healthy People 2030 plan to help address the upstream factors impacting health disparities.

Futhermore, personalized medicine, the understanding that variables like genetics, environment, and lifestyle play a direct role in shaping an individual's response to identical treatment regimens or vaccines, is leading to an evolution in healthcare. Ultimately, each person's unique lived experience, impacted by environment, ethnicity, age, gender, and other societal factors becomes the foundation for their physical and mental well-being.

The Crucial Role of Diversity in Patient Recruitment for Clinical Research Studies

When applied to clinical research, the recognition of social determinants of health amplifies their impact on diverse lived experiences. The imperative arises for our society to ensure the effectiveness of new treatments across all population subgroups. However, recent data reveals a predominant participation of white individuals in clinical research endeavors.

References:

- US Food and Drug Administration 2020 drug trials snapshot. Summary report.

https://www.fda.gov/media/145718/download

- US Food and Drug Administration. Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs guidance for industry.

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial

Advancements in healthcare underscore the variability in how individuals experience the same disease, with certain medications exhibiting distinct efficacy across diverse populations, ages, or genders. It is crucial that safety and efficacy data from clinical research encompass the experiences of all subgroups before treatments receive approval and enter the market. The dearth of diversity in clinical research poses the risk of rendering medications and treatments less effective for specific subgroups.

A notable illustration of this discrepancy is evident in the varying efficacy of beta blockers and ACE inhibitors between individuals of White European and Black African ancestry.

Reference:

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.704023?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

More recently, during the Covid-19 pandemic, preliminary findings from the trial of Moderna’s Covid-19 vaccine were based on a predominantly White participant population—not an adequately representative sample of the U.S. population.

Defining Diversity in Patient Recruitment for Clinical Trials: Profound Research's Perspective

Examining Profound Research's approach to defining diversity involves delving into the specific criteria and considerations we employ. Our definition encompasses factors such as age, gender, ethnicity, socioeconomic status, and other relevant parameters. We adhere to validated (?) guidance from esteemed sources like the NIH and the FDA, utilizing a comprehensive framework that goes beyond conventional criteria. This includes incorporating nuanced parameters that profoundly impact the lived experience of individuals. Our commitment extends further to considering typically underrepresented therapeutic areas or conditions and addressing data gaps across various subpopulations.

References:

https://www.nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html

https://www.fda.gov/consumers/minority-health-and-health-equity/clinical-trial-diversity

Strategies Employed by Profound Research to Enhance Diversity in Patient Recruitment Across Demographic Groups

Profound Research is committed to revealing the proactive measures and approaches undertaken to actively recruit and engage diverse patient populations, with the ultimate goal of ensuring a representative sample in clinical studies.

Our approach is multifaceted, commencing with a focus on geography. We strategically establish partnerships with sites in urban and metro areas. Building upon this foundation, we delineate geographic regions, positioning our sites as central hubs. Recognizing that potential participants prefer local accessibility, we aim to minimize travel distances for involvement in clinical trials or physician visits. Additionally, we actively immerse ourselves in these communities, participating in health fairs and providing screenings and related services. Through the dissemination of information and resources, our objective is to empower local patients, fostering a basis of trust within these communities. We envision the cultivation of this trust as a standard practice, allowing us to recruit patients from diverse backgrounds effectively.

Significance of Geographic Diversity in Patient Recruitment

Centrally addressing the importance of geographic diversity, this discussion emphasizes its pivotal role in advancing the overarching diversity objectives within clinical research studies. The exploration extends to encompass regional health variations, cultural distinctions, and the profound impact of local demographics on the outcomes of the studies.

Furthermore, the positioning of research sites in diverse regional hubs such as San Diego, Los Angeles, and Detroit, paired with diversity of staffing directly contribute to enhancing trial diversity. Recent findings from a white paper by Tufts Center for the Study of Drug Development underscore a significant correlation between the diversity of research site staff and the diversity observed among patients involved in clinical trials.

References: https://medicine.tufts.edu/news-events/news/increase-diversity-clinical-trials-first-increase-staff-diversity

In light of this insight, Profound Research strategically chooses urban areas characterized by vibrant and diverse populations. By establishing partnerships with sites committed to effective practices for engaging and enrolling diverse patients—bolstered by robust infrastructure and streamlined processes—the company is actively contributing to the delivery of expanded treatment options to those who need them most.

Strategies in Overcoming Diversity Challenges for Credible and Relevant Study Findings

Overcoming the primary challenge of recruiting diverse patient populations, particularly centered around trust, is a focal point for Profound Research. Over the years, a pervasive lack of trust has been observed among minority patients within the healthcare system, with historical incidents such as the syphilis research conducted by the U.S. Public Health Service at the Tuskegee Institute of Alabama exemplifying this issue. Language poses a secondary barrier, underscoring the importance of effective communication tailored to patients' comprehension levels regarding potential treatment benefits, possible side effects, and the significance of adherence to treatment regimens. Additionally, logistical hurdles like transportation, employment commitments, and childcare responsibilities can hinder participation.

To address these challenges comprehensively, Profound Research offers external support mechanisms to its research sites, allowing them to concentrate on patient care. Community events held at centers, religious organizations, and farmers markets play a crucial role in building and fostering a relationship of trust with diverse populations. The organization's dedicated team of patient engagement specialists consistently provides education and information to local patient communities, addressing disparities arising from limited access to education. Moreover, Profound has developed concierge-style patient support services, aiding with transportation, childcare, and other potential impediments that might otherwise deter diverse populations from participating in clinical trials.

Conclusion

At its core, individual health is shaped by the intertwined dynamics of physical and mental well-being, profoundly influenced by the lived experience and social determinants of health. Profound Research, by prioritizing diversity and ensuring access to treatment options for all, and through strategic partnerships with like-minded practices, is actively transforming the landscape of clinical research. This commitment aligns with the understanding that addressing diversity challenges and fostering inclusivity not only enhances the credibility and relevance of study findings but also contributes to a more comprehensive and equitable healthcare future.

About the Author: Currently serving as the Senior Director of Patient Recruitment and Engagement for Profound Research, Erem Latif, MS, MBA, is an innovative healthcare leader with experience in leveraging operational excellence, client relationship management and strategic marketing and communications to elevate brand, drive patient engagement, and optimize clinical outcomes. Furthermore, Erem offers a deep understanding of complex industry and proven methodologies to improve results for providers, health systems, and payers.

December 7, 2023

Profound Research and Michigan Healthcare Professionals Forge Path in Neurology: A Q&A with Dr. Esther Young

In the constantly evolving healthcare realm, the collaboration between Profound Research and Michigan Healthcare Professionals emerges as a source of notable progress, particularly within the field of Neurology. Dr. Esther Young, a highly respected neurologist at Michigan Healthcare Professionals, generously shares her experiences in clinical research, offering valuable insights into her motivations, successes, and the significant influence clinical research wields in shaping the future of medicine.

Quick Bio

Dr. Esther Young, D.O., is a highly respected neurologist with a focus on Neurology at Michigan Healthcare Professionals. Holding a certification in neurology, Dr. Young is a member of the American Osteopathic Association and the American Academy of Neurology. Dr. Young is a member of the President’s Council and holds the position of Stroke Director at Troy Beaumont Hospital, contributing her expertise to clinical research trials focused on multiple sclerosis, epilepsy, and stroke. Furthermore, Dr. Young holds roles as an associate clinical professor at Michigan State University, Oakland University, and William Beaumont School of Medicine, while also serving as an assistant professor at the Wayne State School of Medicine.

Dr. Young supports various indications aligning with the needs of her patients, which include but are not limited to:

  • Migraine
  • Alzheimer
  • Multiple Sclerosis
  • Epilepsy
  • Stroke

Find out more about Dr. Young in our Q&A below.

Q1: What led you to clinical research?

"I derive immense satisfaction from engaging in clinical research, driven by a profound fascination with the ever-evolving landscape of neurology. My passion for staying abreast of the cutting-edge developments in this field led me to embark on a journey into research. Specifically, my initial foray into research was motivated by a desire to assist patients in accessing information that was not yet widely available. This commitment to bridging knowledge gaps and providing patients with crucial insights has become a cornerstone of my research endeavors. Through this dual commitment, I not only contribute to the advancement of neurology but also strive to empower patients with information that can shape their healthcare journeys."

Q2: Do you have a particular success story that stuck with you?

"I have vivid recollections of a significant milestone in my clinical research journey, particularly involving Tysabri. Acquiring additional insights into the optimal duration of Tysabri treatment enabled me to advocate for extending the medication period for certain patients beyond conventional expectations. This experience highlighted the tangible impact that advanced information, gleaned through rigorous research, can have on patient care. It reinforced my belief in the transformative potential of clinical research, not only in expanding our knowledge base but also in directly influencing treatment outcomes and enhancing the quality of life for those under our care."

Q3: What would you want people to know about clinical research?

"Delving into the realm of clinical research is not just about individual benefit; it's a collective effort that extends far beyond personal advantages. While clinical research undeniably holds the potential to offer solutions and improvements at an individual level, its overarching impact is in shaping the very future of medicine. It serves as a cornerstone for medical progress, influencing protocols, treatment methodologies, and healthcare standards. By actively participating in and supporting clinical research, we contribute to a broader narrative—one that transcends our immediate circumstances and plays a pivotal role in defining the trajectory of medical advancements for generations to come."

Q4: What are some hobbies/interests of yours outside of clinical research?

"Beyond the intricacies of neurology and my involvement in clinical research, I find immense joy in the simple pleasures of life. I enjoy hanging out with my kids, cherishing precious moments of family time. Additionally, incorporating regular exercise into my routine not only helps me maintain a healthy lifestyle but also adds a dynamic balance to my professional pursuits. These personal interests not only rejuvenate my spirit but also contribute to the holistic approach I bring to both my family life and my role in advancing neurology through clinical research."

Contact Us

Join Profound in advancing novel therapies through community-based clinical trials. We champion diversity, recognizing its vital role in trial success. Our approach brings trials to patients in their own communities, facilitated by dedicated physicians like Dr. Young. If you seek support for your own studies from Dr. Young or any of our distinguished providers, take action today. Contact Profound at https://profoundresearch.io/sponsors.

November 20, 2023

Profound Research and Michigan Health Professionals Announce Clinical Research Partnership and Center of Excellence in Detroit

Detroit, MI – [Nov 20, 2023] – Profound Research (Profound), a leading clinical site network, and Michigan Health Professionals (MHP), a large multi-specialty medical group, today announced a clinical research partnership and the formation of a Clinical Research Center of Excellence in the Detroit metropolitan area.

The Center of Excellence will initially span five locations throughout the Detroit area and will be at the forefront of research in many therapeutic specialties including oncology, cardiology, neurology, and primary care. The partnership will give Profound access to MHP’s extensive network of physicians, and MHP will gain access to Profound’s expertise in patient recruitment, trial execution, and data management.

“We are thrilled to partner with Profound Research to form this Clinical Research Center of Excellence,” said Jeffrey Margolis, MD, President of Michigan Health Professionals. “This partnership will allow us to bring novel therapies to the Detroit community and help us advance the development of new treatments and cures. We are committed to working with Profound to provide our patients with the opportunity to participate in clinical trials that could lead to better treatments for their diseases.”

“The Profound-MHP Clinical Research Center of Excellence is a significant partnership that will unlock new care options to a diverse patient population, something very important to the Profound mission,” said Jonathan Feldstein, MD, President of Profound Research. “MHP is a leading provider of healthcare in the Detroit area, and we share a vision of bringing innovative medicines to support the improvement of patients’ lives in the community.”

This Center of Excellence launched its first sites in Detroit this year and is expecting to reach 10 sites by the end of 2024. Profound Research and MHP have partnered on several studies to date and look forward to launching several more in the coming months.

About Profound Research

Profound Research is an integrated clinical research network composed of trial sites embedded into independent physician practices.  Profound’s mission is to expand access to clinical research for patients in the community and give community physicians more therapeutic options.  Profound Research has locations across Southern California and in the Detroit metropolitan area and is expanding nationwide. The company has a team of experienced and dedicated research professionals who are committed to providing the highest quality clinical research support to physicians and their patients.

About Michigan Health Professionals

Michigan Health Professionals (MHP) is a large multi-specialty medical practice with over 500 physicians and a patient panel of nearly 1 million patients. MHP provides a wide range of medical services, including primary care, specialty care, and surgery. MHP is committed to providing its patients with the highest quality care and improving access to care for patients in the community.

Profound Research LLC, 1213 5th Avenue North, Nashville, TN 37208